Experimental combo therapy aims to tackle devastating breast cancer spread to brain
NCT ID NCT06462092
Summary
This early-stage trial is testing a new combination of two cancer drugs for a severe complication where breast cancer spreads to the lining of the brain and spinal cord. The study aims to see if the treatment is safe and can help control the disease in patients with HER2-negative breast cancer, who currently have very poor survival rates. Researchers will give one drug through an IV and the other directly into the spinal fluid.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEPTOMENINGEAL METASTASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Affiliated Huizhou Hospital, Guangzhou Medical University
RECRUITINGHuizhou, Guangdong, 516000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.